Prevalence of hyperlipidemia in psoriatic arthritis patients in Riyadh, Saudi Arabia

References

1. 1.↵
   1. Queiro R,
   2. Lorenzo A,
   3. Tejón P,
   4. Coto P,
   5. Pardo E

   . Obesity in psoriatic arthritis: comparative prevalence and associated factors. Medicine (Baltimore) 2019; 98: e16400.

   OpenUrlPubMed
2. 2.↵
   1. Gupta S,
   2. Syrimi Z,
   3. Hughes DM,
   4. Zhao SS

   . Comorbidities in psoriatic arthritis: a systematic review and meta-analysis. Rheumatol Int 2021; 41: 275–284.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Raychaudhuri SK,
   2. Chatterjee S,
   3. Nguyen C,
   4. Kaur M,
   5. Jialal I,
   6. Raychaudhuri SP

   . Increased prevalence of the metabolic syndrome in patients with psoriatic arthritis. Metab Syndr Relat Disord 2010; 8: 331–334.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Medina G,
   2. Vera-Lastra O,
   3. Peralta-Amaro AL,
   4. Jiménez-Arellano MP,
   5. Saavedra MA, et al.

   Metabolic syndrome, autoimmunity and rheumatic diseases. Pharmacol Res 2018: 133: 277–288.

   OpenUrlPubMed
5. 5.↵
   1. Han C,
   2. Robinson DW,
   3. Hackett MV,
   4. Paramore LC,
   5. Fraeman KH,
   6. Bala MV

   . Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006; 33: 2167–2172.

   OpenUrlAbstract/FREE Full Text
6. 6.↵
   1. Jafri K,
   2. Bartels CM,
   3. Shin D,
   4. Gelfand JM,
   5. Ogdie A

   . Incidence and management of cardiovascular risk factors in psoriatic arthritis and rheumatoid arthritis: a population‐based study. Arthritis Care Res (Hoboken) 2017; 69: 51–57.

   OpenUrlPubMed
7. 7.↵
   1. Feldman SR,
   2. Zhao Y,
   3. Shi L,
   4. Tran MH,
   5. Lu J

   . Economic and comorbidity burden among moderate‐to‐severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res (Hoboken) 2015; 67: 708–717.

   OpenUrlPubMed
8. 8.↵
   1. Radner H,
   2. Lesperance T,
   3. Accortt NA,
   4. Solomon DH

   . Incidence and prevalence of cardiovascular risk factors among patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis. Arthritis Care Res (Hoboken) 2017; 69: 1510–1518.

   OpenUrlPubMed
9. 9.↵
   1. Tekin NS,
   2. Tekin IO,
   3. Barut F,
   4. Yilmaz Sipahi E

   . Accumulation of oxidized low‐density lipoprotein in psoriatic skin and changes of plasma lipid levels in psoriatic patients. Mediators Inflamm 2007; 2007: 078454.

   OpenUrl
10. 10.↵
    1. Li Q,
    2. Dohey A,
    3. Codner D,
    4. Rahman P

    . POS0044 Evidence of a causal relationship between hyperlipidemia and psoriasis and psoriatic arthritis: A mendelian randomization study. Ann Rheum Dis 2023: 231.
11. 11.↵
    1. Al-Nozha MM,
    2. Arafah MR,
    3. Al-Maatouq MA,
    4. Khalil MZ,
    5. Khan NB,
    6. Al-Marzouki K, et al.

    Hyperlipidemia in Saudi Arabia. Saudi Med J. 2008; 29: 282.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Alzaheb RA,
    2. Altemani AH

    . Prevalence and associated factors of dyslipidemia among adults with type 2 diabetes mellitus in Saudi Arabia. Diabetes Metab Syndr Obes 2020: 4033–440.
13. 13.↵
    1. Vanaclocha F,
    2. Belinchón I,
    3. Sánchez-Carazo JL,
    4. Rivera R,
    5. Carrascosa JM,
    6. Cea-Calvo L, et al.

    Cardiovascular risk factors and cardiovascular diseases in patients with moderate to severe psoriasis under systemic treatment. PSO-RISK, descriptive study. Eur J Dermatol 2014; 24: 662–6629.

    OpenUrlPubMed
14. 14.
    1. Uczniak S,
    2. Gerlicz ZA,
    3. Kozłowska M,
    4. Kaszuba A

    . Presence of selected metabolic syndrome components in patients with psoriasis vulgaris.Postepy Dermatol Alergol 2016; 33: 114–9114.

    OpenUrlPubMed
15. 15.↵
    1. Oh EH,
    2. Ro YS,
    3. Kim JE

    . Epidemiology and cardiovascular comorbidities in patients with psoriasis: A Korean nationwide population‐based cohort study. J Dermatol 2017; 44: 621–629.

    OpenUrlPubMed
16. 16.↵
    1. Karalis D,
    2. Auberson D,
    3. Naqvi S

    : Clinical feature: Gender Differences in the diagnosis and treatment of the metabolic syndrome. National Lipid Association 2015: 1–7.
17. 17.↵
    1. Silva RQ,
    2. Campo EP,
    3. Fernández S,
    4. Rodríguez LA,
    5. Zapico I,
    6. Jirout F

    . POS1080 Hyperlipidemia in psoriatic disease: higher prevalence in psoriatic arthritis and inverse association with systemic therapy. Ann Rheum Dis 2021: 819.
18. 18.↵
    1. Carlsohn A,
    2. Rohn S,
    3. Mayer F,
    4. Schweigert FJ

    . Physical activity, antioxidant status, and protein modification in adolescent athletes. Med Sci Sports Exerc 2010; 42: 1131–1139.

    OpenUrlPubMed
19. 19.↵
    1. Batuca J,
    2. Lamy M,
    3. Neves M,
    4. Batista F,
    5. Paiva-Lopes MJ,
    6. Valverde AH,
    7. Silva M,
    8. Mcvey CE,
    9. Archer M,
    10. Gonçalves J,
    11. Barbas A

    . Anti-apolipoprotein AI (ApoA-I) antibodies have different target epitopes in different clinical conditions. Atherosclerosis 2017; 263: e216–e217.

    OpenUrl
20. 20.↵
    1. Flisiak I,
    2. Klepacki A,
    3. Chodynicka B

    . Plasma and scales levels of interleukin 18 in comparison with other possible clinical and laboratory biomarkers of psoriasis activity. Biomarkers 2006; 11: 194–200.

    OpenUrlPubMed
21. 21.↵
    1. Abrouk M,
    2. Gandy J,
    3. Nakamura M,
    4. Lee K,
    5. Brodsky M,
    6. Singh R, et al.

    Secukinumab in the treatment of psoriasis and psoriatic arthritis: A review of the literature. Skin Therapy Lett 2017; 22: 1–6.

    OpenUrl